Odin PharmaSemaglutide 10 Mg
| Quantity | Discount | Price |
|---|---|---|
| 3–5 | 10% | $162,00 |
| 6–9 | 15% | $153,00 |
| 10–100 | 20% | $144,00 |
Specifications
- Brand: Odin Pharma Peptides & SARMs
- Substance: Semaglutide
- Product Form: Powder
- Dosage: 10 Mg
How To Use
Laboratory Reconstitution & Research Dosing Protocols
Disclaimer: The following information is for educational and laboratory reference only. This product is strictly for in-vitro and in-vivo research and is not intended for human consumption or therapeutic use.
This vial contains 10mg (10,000mcg) of lyophilized Semaglutide powder. Accurate reconstitution is required for precise analytical testing, especially for longitudinal dose-escalation studies.
Reconstitution Guide
For standard research concentration, reconstitute the 10mg vial with 2 ml of Bacteriostatic Water.
- Preparation: Slowly inject the 2 ml of water against the glass wall of the vial.
- Dissolution: Swirl the vial gently until the solution is completely clear. Do not shake.
- Measurement Reference: Using a standard U-100 insulin syringe, 10 Units (0.10 ml) equals exactly 0.5mg (500mcg) of Semaglutide. Therefore, 5 Units (0.05 ml) equals 0.25mg.
Storage Specifications
- Unmixed (Lyophilized): Store at room temperature away from UV light during transport. For long-term preservation, store at -20°C.
- Mixed (Reconstituted): Must be refrigerated (2°C to 8°C). When mixed with Bacteriostatic Water, the solution remains chemically stable for analytical use for up to 8 weeks.
Experience Level Usage Guide
Beginner
Protocol A: Baseline Adaptation & Glycemic Observation
Reference dosing for initial subject acclimation and baseline metabolic tracking.
- Test Subject Dosage: 0.25mg (5 Units) per week.
- Administration: Subcutaneous.
- Observation Period: Maintained for 4 weeks before any dose escalation.
Intermediate
Protocol B: Intermediate Metabolic & Lipolysis Model
Standard clinical escalation for observing significant reductions in adipose tissue mass.
- Test Subject Dosage: 0.5mg to 1.0mg per week.
- Administration: Subcutaneous.
- Observation Period: Escalated gradually (0.5mg for 4 weeks, then 1.0mg for 4 weeks) to mitigate GI distress.
Advanced
Protocol C: Advanced Obesity Resistance Model
Maximum threshold dosing for research subjects displaying high resistance to weight loss.
- Test Subject Dosage: 1.7mg to 2.4mg per week.
- Administration: Subcutaneous.
- Observation Parameter: Strict monitoring of gastrointestinal tolerance and lean muscle mass preservation is required at this tier.
Shipping Details
Detailed Description
What Is Odin Pharma Semaglutide 10 mg?
Semaglutide is a highly modified, long-acting analog of the naturally occurring human GLP-1 hormone. It is specifically formulated to resist degradation by the DPP-4 enzyme, giving it an exceptionally long half-life suited for sustained observational studies.
The 10 mg lyophilized vial by Odin Pharma offers a high-concentration, bulk format. This allows laboratories to conduct extended, multi-phase experimental protocols without the need to switch batches, thereby eliminating data variables and reducing overall research costs.
Please note: Odin Pharma Semaglutide is strictly a research chemical and is not intended for human consumption, therapeutic use, or dietary supplementation.
| Technical Specification | Details |
|---|---|
| Active Compound | Semaglutide (GLP-1 Receptor Agonist) |
| Format | 10 mg Lyophilized Powder (High-Yield) |
| Purity Level | >99% (HPLC & MS Verified) |
| Primary Research Focus | Metabolic Signaling & Glycemic Control |
Observed Benefits in Research Models
In controlled animal testing environments, Semaglutide has consistently demonstrated profound metabolic shifts. Key experimental observations include:
- Glycemic Optimization: Significantly improves insulin sensitivity and stimulates glucose-dependent insulin secretion, making it a primary focus for metabolic syndrome research.
- Gastric Motility Modulation: Induces delayed gastric emptying, which profoundly alters nutrient absorption rates and feeding behavior in test subjects.
- Targeted Adipose Reduction: By interacting with neuro-receptors that control appetite and satiety, it effectively forces a caloric deficit, leading to measurable decreases in visceral and subcutaneous fat.
- Beta-Cell Preservation: Studies indicate a protective effect on pancreatic beta cells, preventing their apoptosis (cellular death) under metabolic stress.
Mechanism of Action
Odin Pharma Semaglutide functions by selectively binding to and activating the GLP-1 receptor. This targeted activation works on multiple fronts: it stimulates the pancreas to secrete insulin when blood glucose is elevated, and simultaneously inhibits the release of glucagon. Furthermore, it crosses the blood-brain barrier to interact directly with the hypothalamus, severely dampening the neuro-signals responsible for appetite and food-seeking behavior in laboratory models.
Comparison: GLP-1 & Metabolic Research Peptides
To design comprehensive metabolic studies, researchers frequently compare Semaglutide with multi-pathway agonists to observe synergistic endocrine responses.
| Research Peptide | Receptor Targets | Comparison to Semaglutide |
|---|---|---|
| Tirzepatide | Dual Agonist (GLP-1 & GIP) | Tirzepatide activates both GLP-1 and GIP receptors for a synergistic metabolic effect, whereas Semaglutide focuses strictly on the isolated GLP-1 pathway. |
| Retatrutide | Tri-Agonist (GLP-1, GIP, Glucagon) | The most advanced multi-pathway model. Semaglutide is preferred when researchers need to study the GLP-1 mechanism in a highly controlled, singular environment. |
| Semaglutide | Single Agonist (GLP-1) | The foundational gold standard for studying appetite suppression and isolated glycemic control. |
Research Preparation & Storage Protocols
The 10 mg lyophilized powder must be reconstituted using bacteriostatic water prior to introduction into experimental models. Precise titration is required due to the compound’s extreme potency.
- Storage (Unmixed): Vials must be kept frozen (-20°C) to maintain stability for prolonged periods.
- Storage (Reconstituted): Once mixed, the solution must be kept in a refrigerator (2°C to 8°C) and utilized within 6 to 8 weeks. Do not agitate or shake the vial.
Potential Side Effects in Toxicology Studies
In animal testing, the primary toxicological observations associated with Semaglutide are gastrointestinal. Researchers frequently record transient nausea, vomiting, and altered bowel habits (constipation or diarrhea) during the initial titration phase. These effects are direct physiological consequences of the delayed gastric emptying mechanism.
Where to Buy Odin Pharma Semaglutide 10 mg Online
The validity of metabolic data relies entirely on the structural integrity of your research materials. Peptidesline supplies verified, laboratory-grade Odin Pharma Semaglutide 10 mg directly from our secure inventory.
- Rapid US Logistics: Shipped directly from our USA facility, ensuring delivery in 4-7 business days.
- Secure Transactions: Checkout smoothly with Zelle or Venmo.
- Crypto Discount: Unlock an instant 10% discount on your entire order by paying with Bitcoin, Ethereum, USDT or Litecoin.
- Click here for Payment Options
FAQ
No. Semaglutide sold by Peptidesline is strictly formulated for in vitro laboratory research and in vivo experimental animal models. It is not approved for human medical use or as a dietary supplement.
The 10 mg bulk vial provides exceptional yield, allowing laboratories to run long-term titration studies over several weeks or months without needing to switch batches, ensuring data consistency.
Semaglutide is a single-agonist that specifically targets the GLP-1 receptor. Tirzepatide is a dual-agonist targeting both GLP-1 and GIP receptors, often resulting in amplified metabolic responses in comparative studies.
Once mixed with bacteriostatic water, the vial must be kept strictly refrigerated at 2°C to 8°C. Because it is highly stable, a properly reconstituted vial can maintain its efficacy for up to 8 weeks.
